Skip to main content
Premium Trial:

Request an Annual Quote

Biotrin Opens R&D Facility to Develop MDx Technology

NEW YORK (GenomeWeb News) – Irish diagnostics shop Biotrin has officially opened its research and development facility in Dublin.

The facility was created as part of the company's project announced last year to develop its automated molecular diagnostics platform technology and assay reagents targeting DNA and RNA in infectious diseases.

The technology is based on loop-mediated isothermal amplification.

On deadline, Biotrin's parent company DiaSorin did not respond to inquiries, but its CEO Carlo Rosa told various publications in Ireland that "The investment is highly significant for the Biotrin Group in that it establishes the Biotrin site in Dublin as DiaSorin's corporate headquarters for molecular diagnostics research, development, and manufacturing."

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.